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OAB incur lower total costs for OAB management when
the cost of incontinence pads are considered.
PRN2
COST-EFFECTIVENESS OF BASILIXIMAB, 
DACLIZUMAB, AND OKT3 AS INDUCTION 
AGENTS IN KIDNEY TRANSPLANTATION
Shin GP, Johnson N, Vasquez E, Walton S
University of Illinois at Chicago, College of Pharmacy, Chicago, 
IL, USA
Basiliximab, daclizumab, and OKT3 are potent immuno-
suppressive induction agents used in kidney transplanta-
tion. All four agents have demonstrated statistically sig-
nificant reductions in the incidence of acute rejection
compared to standard therapy. However, the cost-effec-
tiveness of these induction agents has not been studied in
a uniform context or explored beyond a 1-year period
following transplantation. OBJECTIVE: The purpose of
this study is to estimate cost-effectiveness of basiliximab,
daclizumab, and OKT3 compared to standard therapy
over a 5-year period post transplantation using a societal
perspective. METHODS: A Markov model was con-
structed using four states (eventfree, rejection/graft sur-
vival, graft failure/dialysis, death) to reflect the different
clinical and economic states of transplant patients. The
costs examined included initial hospitalization cost, acute
rejection treatment cost, cost of graft failure and subse-
quent dialysis, cost of maintaining functional graft, and
drug cost for induction agents. The transition probabili-
ties and utilities were obtained from the randomized tri-
als and other literature. Costs were obtained from the US
Renal Data System Annual Report, the University Health-
System Consortium Pharmacy Database, the Red Book,
and literature. RESULTS: Average costs for the first year
post transplantation ranged from $58,052 to $78,153
and five-year total costs were estimated to be $154,806
(basiliximab), $155,712 (daclizumab), $181,113 (OKT3),
and $166,124 (standard therapy). Daclizumab ($48,665/
QALY) and basiliximab ($51,182/QALY) were more
cost-effective than standard therapy ($56,646/QALY) or
OKT3 ($60,391/QALY). CONCLUSION: Preliminary
results suggest that daclizumab and basiliximab are cost-
effective induction agents compared to standard therapy
when considered over a 5-year period following trans-
plantation. Extensive sensitivity analysis is planned to
test the robustness of this finding.
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The prevalence of peritoneal dialysis (PD) in the USA is
12%. PD is less costly and as effective as hemodialysis
(HD) for most patients. OBJECTIVE: To project savings
from a shift in modality distribution (MD) to home-
based therapies. METHOD: We developed a decision
model to assess the cost impact of changes in MD, mo-
dality cost (MC) or numbers of patients. IPD was ex-
cluded. Using 1999 USRDS data, we calculated MC and
applied patient numbers and MD. We previously sur-
veyed US nephrologists who opined optimal MD to max-
imize survival was: hospital HD 9.2%; community full-
care HD 33.9%; community self-care HD 13.8%; home
HD 12.1%; CAPD 17.5%; APD 14.3%; and IPD 1.5%.
To maximize cost-effectiveness the percentages changed
to 4.2, 24.9, 15.5, 16.5, 26.7, 12.4, and 1.0% respec-
tively. The estimated total dialysis spend, excluding epoi-
etin and non-ambulance transportation, was generated
and compared to the total cost using the “optimized”
MD. RESULTS: A total dialysis spend of $11.25 billion
was estimated using MD from the USRDS. The total sav-
ings and additional patients who could be treated at the
MD opined for maximum survival was $750 million
(6.7%) and 15,745, respectively; for maximum cost sav-
ings, $1.06 billion (9.5%) and 22,977. Survey limita-
tions, costing assumptions and modeling suggest caution
that the potential savings identified may or may not be
completely achievable. CONCLUSION: Effecting a change
in MD in accordance with what US nephrologists re-
ported to be acceptable could lead to substantial Medi-
care savings. Strategies to increase utilization of home
and self care therapies, which might include earlier refer-
ral and empowerment of patient choice, should be con-
sidered.
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OBJECTIVE: The objective of this study was to assess
the feasibility and usefulness of administering a quality of
life questionnaire within routine clinical practice with re-
nal patients. METHODS: This was a national 5 centre
study administering a disease-specific questionnaire, the
Renal Quality of Life Profile (RQLP). The RQLP was ad-
ministered by nurses to patients in addition to some de-
mographic and open-ended questions. Nurses reviewed
the completed questionnaire to identify potential areas
requiring discussion and contacted the patient to discuss.
RESULTS: The RQLP was administered to 140 patients:
24 predialysis, 12 home haemodialysis, 25 satellite hae-
modialysis, 21 hospital haemodialysis, 32 CAPD, and 26
transplant. 44% completed the questionnaire in the wait-
ing room, 22% in the consulting room, and 34% on dial-
ysis or at home. During questionnaire review, nurses felt
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there were issues requiring discussion in 46% of patients.
Commonly cited issues were related to holidays, sex life,
tiredness, mobility, and depression. These issues were ei-
ther discussed with the nurse immediately in person
(65%), or the patient was contacted by telephone (28%)
or post (7%). Of those patients who were contacted,
70% were interested in discussing the issues, of whom 3
were referred to andrology clinics and 11 were to be re-
viewed at a future appointment. CONCLUSION: Mea-
surement of QoL is feasible and useful in the routine clin-
ical nursing practice.
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Urge incontinence (UI) significantly affects the physical,
psychological, and economic aspects of the lives of af-
fected individuals. OBJECTIVE: This study assessed the
impact of UI on patients’ health-related quality of life
(HR-QoL) and resource utilization. METHODS: A ques-
tionnaire, administered to ambulatory out-patients diag-
nosed with UI, collected demographic information, mic-
turition and leakage data, HR-QoL and resource use
estimates. HR-QoL was measured using the EuroQoL
(EQ-5D) and King’s Health Questionnaire (KHQ). The
KHQ is a disease-specific instrument which explores
eight domains (health perceptions, incontinence impact,
role, physical and social limitations, personal relation-
ships, emotions, sleep/energy). RESULTS: Patients (n 
60) were 62.5  15.5 years old and 95% female. During
a typical 24-hour period, patients experienced a median
of 3 leakages and a mean of 13 micturitions, 3 of which
occurred nocturnally. Eighty-three percent of patients felt
their condition interfered with their usual activities. The
average utility value determined using the EQ-5D was
0.68. Of the domains of the KHQ, patients indicated the
greatest impairment in the incontinence impact domain.
Other domains considerably affected were sleep/energy
and role and physical limitations. Patients had 102 visits
with healthcare providers and 68 tests/procedures in the
4 weeks preceding the study. Feminine hygiene products,
incontinence pads and diapers were used by 43%, 32%
and 8% of patients at a median of 16, 12 and 7 units per
week, respectively. CONCLUSIONS: UI is a major ob-
stacle to patients’ quality of life, specifically impeding
their sleep and energy level, in addition to causing role
and physical impairments. UI also has considerable impact
on resource utilization.
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There are three limitations in the application of current
HRQL questionnaires related to overactive bladder (OAB):
1) no OAB-specific questionnaire has been developed in
an OAB population with patients experiencing OAB
symptoms but not incontinence; 2) the sample popula-
tions on which such questionnaires have been tested have
been restricted to primarily clinical patients with inconti-
nence; 3) past questionnaires have been developed in fe-
male-only populations. OBJECTIVE: To initiate the de-
velopment of an OAB-specific HRQL questionnaire.
METHODS: Participants were recruited via newspaper
advertisement and screened to ensure they met the study
criteria (predominantly OAB-dry). The groups were gen-
der-specific: Group 1  7 men; Group 2  9 women.
The participants were asked open-ended questions on
symptoms (frequency, urgency and leakage), coping be-
haviors and life impact. Data were analyzed using con-
tent analysis. A draft questionnaire was developed and
reviewed by 88% (14) of the focus group participants
who indicated that the questionnaire captured their
thoughts and experiences. RESULTS: Participants re-
ported significant impact in their HRQL due to OAB in a
variety of domains. The symptoms of frequency, urgency,
and nocturia caused significant alterations in productiv-
ity, travel/commuting, sleep, physical activities, social
functioning, relationships, and psychological well-being,
as well as causing a number of coping behaviors. Most is-
sues were similar between men and women. Men re-
ported interrupted sleep as the greatest area of HRQL
impact; women were unable to identify a single promi-
nent issue or domain. CONCLUSION: This instrument
reflects numerous concerns and issues identified by OAB
focus group participants that were not found in previ-
ously developed questionnaires. It is currently in the vali-
dation phase for future research.
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OBJECTIVE: Overactive bladder (OAB) is a highly prev-
alent condition that can result in substantial changes to
an individual’s daily activities. Behavioral changes to
cope with OAB symptoms are likely to occur early in the
natural history of OAB. In later stages, OAB tends to
